Social Health: The Future of Healthcare Marketing
Newsletters and Deep Dive digital magazine
With advertisers preparing to spend up to $15 billion on influencer marketing by 2022, pharmaceutical and biotech companies are increasingly (and carefully) engaging trusted health social influencers to connect more authentically with consumers.
As pharma starts to leverage a multitude of high-engagement channels like influencer marketing, online communities and virtual health services, the industry finds itself in a unique position to reimagine traditional direct-to-consumer (DTC) efforts and peer-to-peer communication. That means going beyond TV ad celebrities or one-off Instagram relationships limited to short-term PR value.
When it comes to motivating consumers to take action with their health, and especially inspiring people to speak to a doctor, pharma needs to be thinking about new ways not just to reach patients but to activate them.
Social health—the digital means by which health consumers engage with each other and their health—has broad applications for the healthcare industry overall. To learn more, read the full article on health-union.com.
Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies sold directly on the telehealth company's platform.
Oura has launched a trial to see if data collected from its smart rings can help scientists understand physiological changes with obesity treatment.
A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
Astellas Pharma US president Percival Barretto-Ko talks with Dr Paul Tunnah about drug pricing, collaboration and improving the patient experience.
Day One Strategy’s second annual AI in Pharma State of Play report addresses the challenges Pharma Insights teams are facing as AI adoption continues.
As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia
Read Medidata’s 2nd annual survey, 'The State of AI in Clinical Trials. From Pilot to Practice: Insights into AI Adoption, Impact, and Expectations'.
One of the things I enjoyed most about this year’s PM Society PMi Awards was the sheer breadth of the community in the room.
The Marcus Evans 31st Edition Strategic Project & Portfolio Management for Pharma conference, for European pharmaceutical PMO and portfolio leaders.
Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox